Press Releases Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 10:00:51 13/02/2026 pm IST			5-day change	1st Jan Change
125.14 ^CHF	+1.08%		+4.32%	+14.18%

14/02	Sector Update: Health Care Stocks Advance Late Afternoon	MT
14/02	Sector Update: Health Care Stocks Higher Friday Afternoon	MT

Press Releases

13/02	Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy	GL
09/02	Novartis : ESG Data Summary 2025	PU
09/02	Novartis : Update	PU
09/02	Novartis : SASB index	PU
06/02	Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery	GL
06/02	Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery	GL
04/02	Novartis: Q4 Earnings Snapshot	AQ
04/02	Novartis : Report	PU
04/02	Novartis : Earnings Document (q4 2025 investor presentation)	PU
04/02	Novartis : Earnings Document (q4 2025 interim financial report en)	PU
04/02	Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025	GL
30/01	NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX, Relax, It's a Blood Test	AQ
16/01	Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease	GL
15/01	Letter to global governments: A call for bold life sciences investment	PU
09/01	Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment	GL
09/01	Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment	GL
20/12	Novartis and US government reach agreement on lowering drug prices in the US	GL
12/12	Novartis breaks ground on flagship manufacturing hub in North Carolina	GL
12/12	Market Outlook: Injectable Drug Delivery Industry to Top US$1,034.78 Billion by 2030	AQ
09/12	Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses	GL
09/12	1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years	GL
25/11	Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS	GL
25/11	Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)	GL
20/11	Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets	GL
19/11	Novartis announces plans to build flagship manufacturing hub in North Carolina	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Novartis: Markets happy with Novartis's delivery

February 04, 2026 at 10:10 pm IST

Novartis CEO Says They Will Have to 'Tackle Rhetoric' in US Healthcare

January 21, 2025 at 04:26 pm IST